Skip to main
PYPD

PolyPid (PYPD) Stock Forecast & Price Target

PolyPid (PYPD) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

PolyPid Ltd, with a market capitalization of approximately $74 million, is positioned favorably as it approaches a pivotal regulatory milestone for its product candidate D-PLEX100, aimed at preventing surgical site infections. Notably, the favorable feedback received from the FDA during pre-New Drug Application interactions bolsters the outlook for a rolling submission anticipated in early 2026, which, combined with successful regulatory inspections, enhances investor confidence regarding D-PLEX100's potential approval. Furthermore, PolyPid's recent improvements in regulatory clarity, the advancement of its drug delivery platform, and strategic collaborations, such as with AdvanzPharma in the EU, contribute to a positive sentiment among investors as the company transitions towards a commercialization phase.

Bears say

PolyPid Ltd faces substantial risks that contribute to a negative outlook on its stock, primarily due to the potential failure of its clinical candidates to achieve statistically significant results, which could considerably diminish the value of its product portfolio. Additionally, even successful clinical outcomes do not guarantee regulatory approval, which remains a critical hurdle for the company's growth prospects, with vital market entry delays anticipated for key products like D-PLEX100. Compounding these challenges, the company is also exposed to complexities in patent procedures and potential revenue erosion starting in 2036, alongside elevated R&D expenses that exceed consensus expectations, signaling a lack of financial efficiency.

PolyPid (PYPD) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of PolyPid and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About PolyPid (PYPD) Forecast

Analysts have given PolyPid (PYPD) a Strong Buy based on their latest research and market trends.

According to 4 analysts, PolyPid (PYPD) has a Strong Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

PolyPid (PYPD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.